Organization
Kecellitics Biotech
2 clinical trials
Clinical trial
Phase 1/Phase 2 Study of Sequential Chimeric Antigen Receptor T Cell Targeting at CD19 and CD22 B-cell Antigens Treating Refractory or Relapsed B-cell Lymphoma PatientsStatus: Not yet recruiting, Estimated PCD: 2024-12-10
Clinical trial
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell LeukemiaStatus: Not yet recruiting, Estimated PCD: 2023-08-01